CRNX
Price
$31.39
Change
+$0.77 (+2.51%)
Updated
Apr 2 closing price
Capitalization
2.92B
35 days until earnings call
IDYA
Price
$16.35
Change
+$1.58 (+10.70%)
Updated
Apr 2 closing price
Capitalization
1.43B
40 days until earnings call
Ad is loading...

CRNX vs IDYA

Header iconCRNX vs IDYA Comparison
Open Charts CRNX vs IDYABanner chart's image
Crinetics Pharmaceuticals
Price$31.39
Change+$0.77 (+2.51%)
Volume$1.16M
Capitalization2.92B
IDEAYA Biosciences
Price$16.35
Change+$1.58 (+10.70%)
Volume$2.15M
Capitalization1.43B
CRNX vs IDYA Comparison Chart
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. IDYA commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a Hold and IDYA is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (CRNX: $31.39 vs. IDYA: $16.35)
Brand notoriety: CRNX and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 117% vs. IDYA: 216%
Market capitalization -- CRNX: $2.92B vs. IDYA: $1.43B
CRNX [@Biotechnology] is valued at $2.92B. IDYA’s [@Biotechnology] market capitalization is $1.43B. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileIDYA’s FA Score has 0 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • IDYA’s FA Score: 0 green, 5 red.
According to our system of comparison, both CRNX and IDYA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 4 TA indicator(s) are bullish while IDYA’s TA Score has 4 bullish TA indicator(s).

  • CRNX’s TA Score: 4 bullish, 4 bearish.
  • IDYA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both CRNX and IDYA are a good buy in the short-term.

Price Growth

CRNX (@Biotechnology) experienced а -9.04% price change this week, while IDYA (@Biotechnology) price change was -6.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.69%. For the same industry, the average monthly price growth was -9.74%, and the average quarterly price growth was -14.08%.

Reported Earning Dates

CRNX is expected to report earnings on May 08, 2025.

IDYA is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-7.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($2.92B) has a higher market cap than IDYA($1.43B). IDYA YTD gains are higher at: -36.381 vs. CRNX (-38.607). IDYA (-323.14M) and CRNX (-336.07M) have comparable annual earnings (EBITDA) . CRNX has more cash in the bank: 1.35B vs. IDYA (676M). IDYA has less debt than CRNX: IDYA (19.2M) vs CRNX (51.7M). IDYA has higher revenues than CRNX: IDYA (7M) vs CRNX (1.04M).
CRNXIDYACRNX / IDYA
Capitalization2.92B1.43B204%
EBITDA-336.07M-323.14M104%
Gain YTD-38.607-36.381106%
P/E RatioN/AN/A-
Revenue1.04M7M15%
Total Cash1.35B676M200%
Total Debt51.7M19.2M269%
FUNDAMENTALS RATINGS
CRNX vs IDYA: Fundamental Ratings
CRNX
IDYA
OUTLOOK RATING
1..100
5856
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
60
Fair valued
PROFIT vs RISK RATING
1..100
6371
SMR RATING
1..100
9595
PRICE GROWTH RATING
1..100
8994
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (60) in the null industry is in the same range as CRNX (89) in the Pharmaceuticals Major industry. This means that IDYA’s stock grew similarly to CRNX’s over the last 12 months.

CRNX's Profit vs Risk Rating (63) in the Pharmaceuticals Major industry is in the same range as IDYA (71) in the null industry. This means that CRNX’s stock grew similarly to IDYA’s over the last 12 months.

CRNX's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as IDYA (95) in the null industry. This means that CRNX’s stock grew similarly to IDYA’s over the last 12 months.

CRNX's Price Growth Rating (89) in the Pharmaceuticals Major industry is in the same range as IDYA (94) in the null industry. This means that CRNX’s stock grew similarly to IDYA’s over the last 12 months.

CRNX's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as IDYA (100) in the null industry. This means that CRNX’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXIDYA
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
87%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
77%
Momentum
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
73%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 11 days ago
78%
Bullish Trend 22 days ago
77%
Declines
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
76%
Aroon
ODDS (%)
Bearish Trend 1 day ago
68%
Bearish Trend 1 day ago
82%
View a ticker or compare two or three
Ad is loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MINIX42.240.15
+0.36%
MFS International Intrinsic Value I
LCGFX26.59N/A
N/A
William Blair Large Cap Growth I
HSXCX8.88N/A
N/A
Hartford Schroders Diversified Em Mkts C
HBIOX17.58N/A
N/A
Hartford International Opp HLS IB
SUSIX11.57N/A
N/A
State Street Instl US Equity Inv

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with ELVN. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then ELVN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
+2.51%
ELVN - CRNX
51%
Loosely correlated
+5.19%
TRDA - CRNX
49%
Loosely correlated
+0.46%
DNLI - CRNX
49%
Loosely correlated
+11.80%
INZY - CRNX
48%
Loosely correlated
+6.48%
IDYA - CRNX
48%
Loosely correlated
+10.70%
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with GRI. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then GRI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+10.70%
GRI - IDYA
54%
Loosely correlated
-17.33%
KRYS - IDYA
51%
Loosely correlated
+3.68%
RCKT - IDYA
50%
Loosely correlated
+8.43%
IMNM - IDYA
49%
Loosely correlated
+7.19%
XENE - IDYA
49%
Loosely correlated
+2.68%
More